How To Find Unique Opportunities in PE: Roundtable with Drew Schiff, Managing Partner at Aisling Capital (For young CEOs & Founders only)

June 17 2025, 6:00 PM - 7:30 PM EDT Midtown - Address revealed upon registration

Date

Tuesday, June 17th
at
6:00 PM EDT

Location

Midtown - Address revealed upon registration

About

Osher roundtables are engaging, educational, unparalleled learning experiences for young professionals. Conversations are candid and off the record, allowing you opportunity to partake in the discussion and ask questions.

This roundtable is intended for young CEO's, Founders, and top-decision makers who have at least $2m in revenue, 15+ employees, or over $100m assets under management.

For questions about the event or membership please reach out to: brooke.steinman@osherpartners.org

Attendee Policy
Osher Programs are open to professionals from the ages of 26-40. If you are interested in attending, please apply by clicking the "register" button. A member of our team will review your information and get back to you shortly. If you are over age 40 and do not qualify for this session, we will be happy to provide further information on involvement opportunities for which you do qualify. Non-members of Osher are welcome to join one event to experience our group. After your first event we ask that you apply to become a member if you wish to continue being involved in our community.

Non-Solicitation Policy
Osher has a non-solicitation policy covering all of our conferences and events. In order to provide a distraction-free environment for our mentors, sponsors, attendees, and employees, we do not allow solicitation at our events by attendees or unauthorized parties without the express written permission or consent from Osher.

Speaker

Andrew Schiff, MD

Managing Partner at Aisling Capital

Dr. Schiff joined Aisling in 2000 and serves as one of the Managing Partners. Prior to Aisling, Dr. Schiff practiced internal medicine for six years at the New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine.

Dr. Schiff currently serves as a director of Aclaris Therapeutics, Dren Bio, and Monte Rosa Therapeutics. Additionally, Dr. Schiff serves as a board observer of Antios Therapeutics and Prolacta Biosciences. His prior board service includes Adams Respiratory Therapeutics (acquired by Reckitt Benckiser), Agile Therapeutics, ArgiNOx Pharmaceuticals, ARMGO Pharma, Barrier Therapeutics (acquired by Stiefel Laboratories), Bioenvision (acquired by Genzyme), CardioKine (acquired by Cornerstone), Cempra Pharmaceuticals, F2G, Harmony Biosciences, Miramar Labs (acquired by Sientra), Myogen (acquired by Gilead Sciences), PowerVision (acquired by Alcon), Quintiles (now IQVIA), SkinMedica (acquired by Allergan), Sirion Therapeutics (licenses acquired by Alcon), TransEnterix, Zavante Therapeutics (acquired by Nabriva) and ZELTIQ Aesthetics (acquired by Allergan). He is a longtime supporter and board member of the Visiting Nurse Service of New York.

Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia Business School, and his B.S. with honors in Neuroscience from Brown University.